Details for New Drug Application (NDA): 050789

NDA 050789 describes TOBRAMYCIN SULFATE, which is a drug marketed by Apothecon, Baxter Hlthcare Corp, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hospira, Igi Labs Inc, Mylan Labs Ltd, Slate Run Pharma, Teva Pharms Usa, Watson Labs Inc, Xellia Pharms Aps, and Xgen Pharms, and is included in thirty-two NDAs. It is available from eleven suppliers. Additional details are available on the TOBRAMYCIN SULFATE profile page.

The generic ingredient in TOBRAMYCIN SULFATE is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.

Summary for 050789

Tradename:	TOBRAMYCIN SULFATE
Applicant:	Fresenius Kabi Usa
Ingredient:	tobramycin sulfate
Patents:	0

Pharmacology for NDA: 050789

Suppliers and Packaging for NDA: 050789

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
TOBRAMYCIN SULFATE	tobramycin sulfate	INJECTABLE;INJECTION	050789	NDA	Fresenius Kabi USA, LLC	63323-303	63323-303-55	6 VIAL, PHARMACY BULK PACKAGE in 1 TRAY (63323-303-55) / 30 mL in 1 VIAL, PHARMACY BULK PACKAGE (63323-303-21)
TOBRAMYCIN SULFATE	tobramycin sulfate	INJECTABLE;INJECTION	050789	NDA	Fresenius Kabi USA, LLC	63323-303	63323-303-51	6 VIAL, PHARMACY BULK PACKAGE in 1 TRAY (63323-303-51) / 30 mL in 1 VIAL, PHARMACY BULK PACKAGE (63323-303-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	EQ 1.2GM BASE/VIAL
Approval Date:	Jul 13, 2004	TE:	AP	RLD:	No

Complete Access Available with Subscription